ArticleEuropean radiology2026
Clinical use of coronary computed tomography angiography-derived fractional flow reserve: expert consensus by an International Working Group.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FFR-CT: Technical Advances and Implementation in Clinical Practice.Journal of imaging · 2026Review
- Association between region-specific epicardial adipose tissue and CT-derived fractional flow reserve-defined myocardial ischemia: a retrospective coronary CTA study stratified by hypertension and type 2 diabetes mellitus.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectivesCoronary computed tomography angiography (CCTA)-derived fractional flow reserve (CT-FFR) has emerged as a critical tool for assessing functional ischemia in coronary artery disease (CAD). This expert consensus, developed by an international working group, provides a comprehensive overview of the clinical applications, diagnostic performance, and future perspectives of CT-FFR. METHODS AND
resultsThe consensus highlights the use of CT-FFR as an indicator for abnormal coronary physiology, demonstrating superior diagnostic performance over anatomical CCTA alone, with pooled accuracy of 71%-91%, sensitivity of 76%-98% and specificity of 61%-94% at the per-vessel level, particularly in intermediate lesions. It also addresses factors influencing CT-FFR's diagnostic performance, including technical, physiological, and measurement-related considerations. The document discusses the role of CT-FFR in decision-making, serving as a gatekeeper for invasive coronary angiography (ICA) and aiding in percutaneous coronary intervention (PCI) planning. Additionally, CT-FFR shows promise as a prognostic marker, with lower CT-FFR values associated with a higher risk of major adverse cardiovascular events (MACE). Economic evaluations indicate that CT-FFR is cost-effective compared to traditional non-invasive strategies. The consensus also explores the application of CT-FFR in complex lesions and non-atherosclerotic diseases, such as myocardial bridging and anomalous aortic origin of coronary arteries. Future directions include the development of more accurate CT-FFR approaches and the exploration of CT-FFR-based risk stratification.
conclusionsThis consensus aims to provide guidance for radiologists, cardiologists, and other healthcare professionals, promoting the standardized and evidence-based use of CT-FFR in clinical practice. KEY POINTS: Question Inconsistent implementation and evidence gap of CT-derived fractional flow reserve need an international consensus to optimize functional assessment of coronary artery disease and downstream management. Findings This consensus standardizes CT-derived fractional flow reserve application, validating its diagnostic performance (accuracy 71%-91%, sensitivity 76%-98%, specificity 61%-94%), utility in guiding revascularization, and prognostic value. Clinical relevance Standardized CT-derived fractional flow reserve use can optimize patient management by effectively reducing unnecessary invasive coronary angiography, guiding targeted revascularization, and improving risk prediction based on lesion-specific physiology.
Indexed as
Identifiers
41686239What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.